MAO-B inhibitors

MAO-B inhibitors

Inhibitors of the enzyme monoamine oxidase B. MAO-B helps break down dopamine; inhibiting it prolongs the action of dopamine in the brain. Selegiline is an MAO-B inhibitor.
Mentioned in: Parkinson Disease
References in periodicals archive ?
Results show that the tested substances are powerful selective MAO-B inhibitors, yet with the reversible type of inhibition typical of natural substances and plausibly devoid of any significant side effects.
A number of MAO-B inhibitors used in the clinical setting for treating Parkinson's disease have unwanted side effects.
Agents such as the dopamine agonists, COMT inhibitors and MAO-B inhibitors can assist in addressing these.
Depression in patients with dementia can be treated with selected tricyclics, MAO-B inhibitors, and selective serotonin reuptake inhibitor medications.
Increasing use of MAO-B inhibitors is mostly attributed to Azilect, which demonstrated in the ADAGIO Phase III trial in early PD patients the ability to retard disease progression in addition to providing mild symptomatic relief from motor systems.
Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.
Selective MAO-B inhibitors, like Azilect([R]), do not generally interfere with tyramine breakdown and elimination at recommended doses.
These shifts may suggest a growing preference for dopamine agonists over MAO-B inhibitors in treatment-naive patients, most likely in the early stages of PD-a finding that could be attributed to U.
Despite the ADAGIO clinical trial results, which demonstrated a mild disease-modifying effect for Teva/Lundbeck's Azilect (an MAO-B inhibitor), surveyed physicians prescribe MAO-B inhibitors as first-line therapy much less frequently than dopamine agonists.
Compared with primary care physicians, surveyed neurologists less frequently use levodopa as first-line therapy for patients with mild disease under the age of 65 and are increasingly using dopamine agonists and MAO-B inhibitors to manage mild motor symptoms and delay the need for levodopa.
9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.